FAKTOR-VIII-POLYPEPTIDFORMULIERUNGEN

European patent · EP3666283 · In force

Register entry

Publication number
EP3666283
Application number
EP19212900
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 14, 2014
Published
Jun 17, 2020
Granted
Jun 8, 2022
Protection ends at the latest
Mar 13, 2034
Next annual fee due
Mar 31, 2027
IPC classes
A61K 38/37 (2006.01)
A61P 7/00 (2006.01)
A61P 7/04 (2006.01)
A61P 43/00 (2006.01)
Priority
US 201361800293 P 15.03.2013
US 201361817085 P 29.04.2013
US 201361829884 P 31.05.2013
US 201361839477 P 26.06.2013
US 201361863860 P 08.08.2013
US 201361876927 P 12.09.2013
US 201361879955 P 19.09.2013
US 201361897742 P 30.10.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. Apr 19, 2023

    Change

    Published in Swissreg on 19.04.2023

  5. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  6. Jun 8, 2022

    Granted

    Published in Swissreg on 08.06.2022

Parties

Holder

Bioverativ Therapeutics Inc.

225 Second Avenue, Waltham MA 02451, US

Inventor

ABDUL-FATTAH, Ahmad

Cambridge, MA Massachusetts 02142, US

GAGE, Daniel

Cambridge, MA Massachusetts 02142, US

MALONEY, Kevin

Cambridge, MA Massachusetts 02142, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.